Network Insights Methodology Whitepaper Get Access

Sanofi

ORG Health Care / Pharmaceuticals Momentum 6.8ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$60.4B market cap (Paris) manufactures diabetes, oncology, and vaccine therapeutics. FDA approved diabetes drug for pediatric stage 3 patients in June 2026; halted riliprubart nerve disease trial, signaling portfolio recalibration under new R&D strategy.

Recent pipeline setbacks including discontinuation of riliprubart late-stage nerve disease study; ongoing portfolio optimization across diabetes and obesity segments.
-0.92
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
6.8
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
9
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Sanofi is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Connected Entities
FDA Merck Europe PlocamiumAI AstraZeneca California Paris CEO Pfizer
Watch This Entity
PSI Intelligence
30-Day Trend
2026-05-14 2026-06-13 9 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.265
Spectral Shift
407.175
Sentiment-Momentum Divergence
0.000
Source Concentration
0.540
Signal
Sanofi is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Driver
Ranked #89 of 90 in Health Care — unusually quiet vs peers (-3.3 sigma below). PSI down 0.32 from yesterday (-0.61 -> -0.92).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
89 of 90
Sector Rank
-3.34
Peer Z-Score
1%
Sector Percentile
Network Analysis
9 Degree Centrality
Ego Network (top connections)
FDA (weight 13.0)Merck (weight 7.0)Europe (weight 5.0)PlocamiumAI (weight 5.0)AstraZeneca (weight 4.0)California (weight 3.0)Paris (weight 2.0)CEO (weight 2.0) FDAMerckEuropePlocamiumAIAstraZenecaCaliforniaParisCEO Sanofi (degree 9) Sanofi
Centrality History
2026-05-14 2026-06-13 9 0 Degree Mentions
EntityWeight StatusFirst Seen
FDA 13 NEW
Merck 7 NEW
Europe 5 NEW
PlocamiumAI 5 NEW
AstraZeneca 4 NEW
California 3 NEW
Paris 2 NEW
CEO 2 NEW
Pfizer 1 NEW
Article Coverage (14)
DateLaneTitle
2026-05-28 Healthcare M&A Apogee Secures $1.3 Billion From Blackstone as Alternative Capital Reshapes Biotech Financing
2026-04-23 Healthcare M&A Pharma Giants Capitulate as Trump Wins Initial Pricing Concessions, Signals Escalation Ahead
2026-03-28 Healthcare M&A A Week of Bolt-On Deals; Wave Crashes on Obesity Data; Sanofi Partners With TCE Startup; and More
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-23 Healthcare M&A Sanofi Extends $180M to California T Cell Engager Startup Kali

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-06-13 ← Intelligence Network